Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Anti-idiotypic
Reexamination Certificate
2005-09-27
2005-09-27
Siew, Jeffrey (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Anti-idiotypic
C435S007100, C435S327000, C530S350000, C530S387100, C530S387200, C530S387300, C530S388100, C530S391300, C424S133100, C424S141100
Reexamination Certificate
active
06949244
ABSTRACT:
The present invention provides a monoclonal anti-idiotype antibody 11D10 that elicits an immune response against a specific epitope of a high molecular weight mucin of human milk fat globule (HMFG) and a hybridoma that produces 11D10. The hybridoma that produces 11D10 was selected by specific procedures. 11D10 induces an immunological response to HMFG in nice, rabbits, monkeys and patients with advanced HMFG-associated tumors. This invention provides compositions derived from polynucleotide sequences encoding the variable light and/or variable heavy regions of monoclonal anti-idiotype antibody 11D10, as well as polypeptides encoded thereby. The invention also provides compositions which can be used in the detection or treatment of HMFG-associated tumors.
REFERENCES:
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4436728 (1984-03-01), Ribi et al.
patent: 4675287 (1987-06-01), Reisfeld et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4693966 (1987-09-01), Houghton et al.
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 4726947 (1988-02-01), Shimada et al.
patent: 4754065 (1988-06-01), Levenson et al.
patent: 4800159 (1989-01-01), Mullis et al.
patent: 4904596 (1990-02-01), Hakomori
patent: 4918164 (1990-04-01), Hellstrom et al.
patent: 5009995 (1991-04-01), Albino et al.
patent: 5053224 (1991-10-01), Koprowski et al.
patent: 5057540 (1991-10-01), Kensil et al.
patent: 5077284 (1991-12-01), Loria et al.
patent: 5091177 (1992-02-01), Hellstrom et al.
patent: 5134075 (1992-07-01), Hellstrom et al.
patent: 5171568 (1992-12-01), Burke et al.
patent: 5208146 (1993-05-01), Irie
patent: 5240833 (1993-08-01), Nudelman et al.
patent: 5242824 (1993-09-01), Hellstrom et al.
patent: 5270202 (1993-12-01), Raychaudhuri
patent: 5407684 (1995-04-01), Loria et al.
patent: 5808033 (1998-09-01), Gourlie et al.
patent: 5840299 (1998-11-01), Bendig et al.
patent: 6274143 (2001-08-01), Chatterjee et al.
patent: 0 141 783 (1985-05-01), None
patent: 0280209 (1988-08-01), None
patent: 0 438 803 (1991-07-01), None
patent: 0329400 (1993-09-01), None
patent: WO 86/00909 (1986-02-01), None
patent: WO 89/07268 (1989-08-01), None
patent: WO 89/11537 (1989-11-01), None
patent: WO91/0996 (1991-07-01), None
patent: WO 91/11465 (1991-08-01), None
patent: WO 91/11508 (1991-08-01), None
patent: WO 91/16924 (1991-11-01), None
patent: WO 92/08495 (1992-05-01), None
patent: WO 92/16231 (1992-10-01), None
patent: WO 93/06233 (1993-04-01), None
patent: WO 94/05329 (1994-03-01), None
patent: WO 94/11508 (1994-05-01), None
patent: WO 94/11508 (1994-05-01), None
patent: WO-91/09967 (1999-07-01), None
patent: WO 02/40501 (2002-05-01), None
Kofler R, et al. J Clin Invest Sep. 1988; 82: 852-60.
Tripathi PK, et al. Hybridoma 1999; 18 (2): 193-202.
Depalncq D, et al. Protein Eng Aug. 1994; 7 (8): 1027-33.
Goldenberg DM. Am J Med Mar. 1993; 94: 297-312.
Carter P, et al. Proc Natl Acad Sci USA Mar. 1992; 89: 4285-9.
Alfthan K, et al. Protein Eng Jul. 1995; 8 (7): 725-31.
Bodey B, et al. Anticancer Res 2000; 20: 2665-76.
Berinstein N, et al. J Immunol Apr. 15, 1988; 140 (8): 2839-45.
Berinstein N, et al. J Immunol Aug. 1, 1987; 139 (3): 971-6.
Hurwitz E, et al. Int J Cancer May 15, 1986; 37 (5): 739-45.
Campbell MJ, et al. J Immunol Aug. 1, 1990; 145 (3): 1029-36.
Tao MH, et al. Nature Apr. 22, 1993; 362 (6422): 755-8.
Chen TT, et al. J Immunol Nov. 15, 1994; 153 (10): 4775-87.
Basham TY, et al. J Immunol Nov. 1, 1986; 137 (9): 3019-24.
Yu Z, et al. J Clin Invest Aug. 2002; 110 (3): 289-294.
Bocchia M, et al. Haematologica 2000; 85: 1172-1206.
Zeytin HE, et al. Cancer Gene Ther 2000; 7 (11): 1426-36.
Benvenutti F, et al. Gene Ther 2001; 8: 1555-61.
Benvenutti F, et al. Gene Ther 2000; 7: 605-11.
Gavilondo JV, et al. Biotech Jul. 2000; 29: 128-45.
Kennedy RC, et al. Biotech 1985; 3 (5): 404-10.
Skolnick J, et al. Trends Biotechnol 2000; 18 (1): 34-39.
Chatterjee et al (Journal of Immunology, 1988, vol. 141:1398-1403).
Lewin Science vol. 237 1570, 1987.
Reeck et al Cell vol. 50 667, 1987.
Paul Fundamtenal Immunology p. 242 third edition, 1993.
Chatterjee et al Cancer Immuno Immunother vol. 38 75-82, 1994.
Rudikoff et al Proc Natl Acad Sci USA vol. 79 1979, 1982.
Panka et al Proc Natl Acad Sci USA vol. 85 3080-3084, May 1988.
Amit et al Science vol. 233 747-753, 1986.
Houdebine, L-M. (1994). “Production of Pharmaceutical Proteins From Transgenic Animals,”Journal of Biotechnology34:269-287.
Kavaler, J. et al. (1990). “A Set of Closely Related Antibodies Dominates The Primary Antibody Response To The Antigenic Site CB of The A/PR/8/34 Influenza Virus Hemagglutinin,”J. Immun.145(7):2312-2321.
Liu, A. Y. et al. (1987). “Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 With Potent Fc-Dependent Biologic Activity,”J. Immunol.139(10):3521-3526.
Mo, J. A. et al. (1993). “Variable Region Gene Selection of Immunoglobulin G-Expressing B Cells With Specificity For a Defined Epitope On Type II Collagen,”Eur. J. Immunol.23:2503-2510.
Pandha, H. S et al. (2000). “Oncologial Applications of Gene Therapy,”Current Opinion in Investigation Drugs1(1):122-134.
Pandya, K. J. et al. (1985). “A Retrospective Study of Earliest Indicators of Recurrence in Patients On Eastern Cooperative Oncology Group Adjuvant Chemotherapy Trials For Breast Cancer. A Preliminary Report,”Cancer55(1):202-205.
Patterson, A. P. (2003). Principles Investigators for Human Gene Transfer Trials Employing Retroviral Vectors. Notification of a Serious Adverse Event.Department of Health and Human Service,pp. 1-3.
Schouten, D. et al. (1993). “Development of Lipoprotein-like Lipid Particles for Drug Targeting Neo-High Density Lipoproteins,”Molecular Pharmacology44(2):486-492.
Seidman, J. G. et al. (1979). “A κ-Immunoglobulin Gene is Formed by Site-Specific Recombination without Further Somatic Mutation,”Nature280(5721):370-375.
Shlomchik, M. et al. (1990). “Anti-DNA Antibodies from Autoimmune Mice Arise by Clonal Expansion and Somatic Mutation,”J. Exp. Med.171(1):265-297.
Stevenson, F. K. et al. (1995). “Idiotypic DNA Vaccines Against B-Cell Lymphoma,”Immunological Reviews145:211-228.
Verma, I. M. et al. (1997). “Gene Therapy-Promises, Problems, Problems and Prospects,”Nature389:239-242.
Amalfitano, A.et al. (2002). “Separating Fact From Fiction: Assessing the Potential of Modified Adenovirus Vectors for Use in Human Gene Therapy,”Current Gene Therapy2(2):111-133.
Berzoksky, J.A. and Berkower, I.I. (1993). “Immunogencity and Antigen Structure,” Chapter 8In Fundamental Immunology,William E. Paul ed., Raven Press NY, p. 242.
Browning, J. L. et al. (1993). “Lymphotoxin β, a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface,”Cell(72):847-856.
Darsley, M. J. et al. (1985). “Nucleotide Sequences of Five Anti-Lysozyme Monoclonal Antibodies,”EMBO J.4(2):393-398.
De Waele, P. et al. (1988). “Expression in Non-Lymphoid Cells of Mouse Recombinant Immunoglobulin Directed Against The Tumour Marker Human Placental Alkaline Phosphatase,”Eur. J. Biochem.176:287-295.
Gaida et al., (1992), “A monoclonal anti-idiotypic antibody bearing the image of an epitope specific to the human carcinoembryonic antigen,”Int. J. Cancer51(3), 459-465.
Moraes et al., (1992) “Induction of an immune response through the idiotypic network with monoclonal anti-idiotype antibodies in the carcinoembryonic antigen system,”J. Cell Biochem50(3), 324-335.
Altschul et al., “Basic local alignment search tool” (1990)J. Mol Biol. 215:403-410.
Barry et al., “Protection against mycoplasma infection using expression-library immunization” (1995)Nature 377:632-635.
Bhattacharya-Chatterjee et al., “Anti-idiotype antibodies as potential therapeutic agents for human breast cancer”Antigen and Antibody Molecular Engineering
Chatterjee Malaya
Chatterjee Sunil K.
Foon Kenneth A.
Morrison & Foerster / LLP
Rawlings Stephen L.
Siew Jeffrey
The Board of Trustees of the University of Kentucky
LandOfFree
Murine monoclonal anti-idiotype antibody 11D10 and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Murine monoclonal anti-idiotype antibody 11D10 and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Murine monoclonal anti-idiotype antibody 11D10 and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3375762